Henrik Winther Schytz Selected Research

Henrik Winther Schytz Research Topics

Disease

21	Migraine Disorders (Migraine) 04/2024 - 01/2009
17	Headache (Headaches) 02/2024 - 01/2009
4	Pain (Aches) 01/2022 - 08/2010
3	Post-Traumatic Headache 01/2024 - 06/2020
3	Migraine with Aura (Familial Hemiplegic Migraine) 09/2023 - 12/2015
3	Epilepsy (Aura) 09/2023 - 03/2016
3	Neurogenic Inflammation 12/2022 - 08/2010
3	Hypoxia (Hypoxemia) 12/2017 - 03/2016
2	Brain Concussion (Cerebral Concussion) 10/2020 - 06/2020
2	Migraine without Aura (Common Migraine) 11/2018 - 01/2009
2	Acute Pain 12/2010 - 08/2010
1	Tension-Type Headache (Tension Headache) 04/2024
1	Neck Pain (Cervicalgia) 02/2024
1	Post-Concussion Syndrome 01/2024
1	Secondary Headache Disorders 01/2023
1	Cognitive Dysfunction 01/2023
1	Ischemic Stroke 01/2023
1	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2022
1	COVID-19 09/2021
1	Venous Thrombosis (Deep-Vein Thrombosis) 09/2021
1	Hypersensitivity (Allergy) 01/2021
1	Ganglion Cysts (Ganglion) 01/2020
1	Cluster Headache (Cluster Headaches) 11/2016
1	Acidosis 08/2014
1	Obstructive Sleep Apnea 05/2013

Drug/Important Bio-Agent (IBA)

9	Calcitonin Gene-Related PeptideIBA 01/2024 - 11/2016
6	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 05/2018 - 01/2009
3	Tryptamines (Triptans)IBA 10/2022 - 01/2017
3	salicylhydroxamic acid (SHAM)IBA 01/2020 - 03/2016
3	Adenylyl Cyclases (Adenylyl Cyclase)IBA 01/2018 - 12/2010
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2017 - 12/2010
2	Carbon MonoxideIBA 11/2018 - 01/2018
2	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 01/2018 - 12/2010
2	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2017
1	candesartanIBA 04/2024
1	Mirtazapine (Rexer)FDA LinkGeneric 04/2024
1	Type A Botulinum Toxins (Botox)FDA Link 02/2024
1	incobotulinumtoxinA FDA Link 02/2024
1	eptinezumabIBA 01/2023
1	Interleukin-6 (Interleukin 6)IBA 12/2022
1	Transforming Growth Factor beta (TGF-beta)IBA 12/2022
1	CytokinesIBA 12/2022
1	Interleukin-10 (Interleukin 10)IBA 12/2022
1	SolutionsIBA 11/2022
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 11/2022
1	VaccinesIBA 09/2021
1	COVID-19 VaccinesIBA 09/2021
1	erenumabIBA 06/2020
1	Monoclonal AntibodiesIBA 06/2020
1	Therapeutic UsesIBA 06/2020
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 01/2019
1	Adenosine Monophosphate (AMP)IBA 01/2019
1	CarboxyhemoglobinIBA 11/2018
1	GasotransmittersIBA 11/2018
1	Pituitary Adenylate Cyclase-Activating Polypeptide ReceptorsIBA 05/2018
1	AntibodiesIBA 01/2018
1	Substance PIBA 01/2017
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2017
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2017
1	Serotonin (5 Hydroxytryptamine)IBA 01/2017
1	Nitroglycerin (Dynamite)FDA LinkGeneric 11/2016
1	Glutamic Acid (Glutamate)FDA Link 03/2016
1	Lactic Acid (Lactate)FDA LinkGeneric 03/2016
1	Carbonic Anhydrase InhibitorsIBA 08/2014
1	Acetazolamide (Diamox)FDA LinkGeneric 08/2014
1	Sumatriptan (Imigran)FDA LinkGeneric 01/2012
1	Type I Pituitary Adenylate Cyclase-Activating Polypeptide ReceptorsIBA 12/2010
1	Carbachol (Carbastat)FDA Link 12/2010
1	Acetylcholine (Acetylcholine Chloride)FDA Link 12/2010
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2009

Therapy/Procedure

2	Intravenous Infusions 09/2023 - 01/2021
2	Therapeutics 01/2017 - 05/2013
1	Neurological Rehabilitation 01/2023
1	Continuous Positive Airway Pressure 05/2013
1	Intradermal Injections 08/2010
1	Lasers (Laser) 08/2010